FDA Opens Docket on Ibogaine Trial Design and Safety

FDA published a Request for Information on 6 October 2026 describing, in unusual detail, how it is currently thinking about the design of early-phase clinical trials for ibogaine — a psychoactive alkaloid with a well-documented cardiac risk profile that has mostly existed outside the regulated drug-development system in the United States. The agency is not reviewing a specific application; it is previewing dosing, eligibility, and safety-monitoring expectations before any sponsor has filed an Investigational New Drug application, and asking the public and prospective sponsors to weigh in by 20 November.

Why FDA is publishing trial design before a sponsor asks

Sponsors ordinarily learn FDA's view of a trial design through direct interaction — a pre-IND meeting, a clinical hold letter, a response to a specific protocol. An RFI that lays out dosing ceilings and exclusion criteria in the Federal Register, before any IND is on file, is a different and less common move. It signals that FDA expects applications to arrive soon enough that it wants its baseline expectations on the public record first, and it gives prospective sponsors — including academic groups and the federally funded programs now standing up ibogaine research — a shared starting point rather than each negotiating the same cardiac-safety questions from scratch.

The cardiac risk the whole design turns on

Ibogaine's regulatory story cannot be separated from its safety profile: it is associated with QT-interval prolongation and torsades de pointes, a potentially fatal arrhythmia, and case reports of cardiac deaths following unsupervised or underground use are part of the record FDA is working against. The RFI's specifics read as a direct response to that risk — a dose ceiling, an inpatient setting with intensive monitoring, and exclusion criteria aimed squarely at patients whose cardiac or psychiatric history would compound the danger. Sponsors should treat the 10 mg/kg starting-dose ceiling and the QTcF-based exclusion as the clearest signal yet of where FDA's safety floor sits, even though the RFI is soliciting comment rather than finalizing a requirement.

A different angle from FDA's other psychedelics actions

This RFI is distinct from FDA's broader psychedelics work this year on therapy access and provider credentialing. Those proceedings addressed who should be allowed to administer psychedelic-assisted therapy once a drug is approved. This RFI addresses an earlier and narrower question — how a specific molecule's first-in-protocol clinical trials should be designed — and applies to ibogaine specifically because of its distinctive cardiac risk, not to psychedelics as a class.

• What it is: a Request for Information, not a guidance document or a decision on any pending application.
• What FDA is asking about: patient population and eligibility, dose selection and escalation, cardiac and neurologic safety monitoring, and informed consent and independent safety oversight.
• The headline numbers: a starting dose not exceeding 10 mg/kg, an 18-to-55 age window, and exclusion for a prolonged QTcF interval or a family history of arrhythmia or cardiac death.
• The deadline: comments to the docket are due 20 November 2026.

Frequently asked questions

What did FDA publish on ibogaine, and when?

A Request for Information, "Design and Safety Considerations for Clinical Trials Involving Ibogaine Drug Products," in the Federal Register on 6 October 2026 (FR Doc. 2026-20427), alongside an FDA press release, "FDA Seeks Public Input to Support Ibogaine Research." Comments are due 20 November 2026.

What dosing approach does FDA describe?

FDA's preliminary thinking favors small, sequential dose-ascending cohorts with a starting dose not exceeding 10 mg/kg, with an initial trial likely administering a single dose in an intensively monitored inpatient setting.

What safety limits does the RFI propose for an initial trial population?

FDA describes limiting early trials to adults aged 18 to 55 who have stopped taking psychiatric medications, excluding those with a prolonged QTcF interval, a family history of arrhythmia or cardiac death, or current suicidal thoughts or behavior — reflecting ibogaine's known association with QT-interval prolongation and torsades de pointes.

Why is FDA doing this now?

The RFI advances President Trump's 18 April 2026 executive order on accelerating medical treatments for serious mental illness, which directed federal agencies to speed research into psychedelic compounds. HHS has said it is prioritizing federally supported ibogaine research in two populations: adults with opioid use disorder and adults with post-traumatic stress disorder.